Table 2

Summary of clinical trial outcomes and practical considerations

	Omalizumab	Mepolizumab	Reslizumab	Benralizumab	Dupilumab	Tezepelumab^¶
Biomarkers associated with reduction in exacerbation rate
Blood eosinophils, cells·μL⁻¹	≥260^#	≥300	≥400	≥300	≥300	≥150
F_ENO, ppb	≥19.5	Not associated	Not associated	Not associated	≥25	≥25
Outcomes
Exacerbation rate reduction⁺	25%^§	∼50%	∼40%	∼50%	∼70%	∼70%
mOCS reduction		++		++	++
Quality of life improvement	+	+	+	+	+	++
FEV₁ improvement^ƒ	+/−	+	+/−	+	++	++
Treatment of comorbidities
CRwNP^##	++	++		+	++^¶¶
Atopic dermatitis					++
Chronic urticaria	+
EGPA		++	+	+
Practical considerations
Frequency	2–4 weekly	4 weekly	4 weekly	8 weekly	2 weekly	4 weekly
Route	s.c. variable dose⁺⁺	s.c. fixed dose	i.v.	s.c. fixed dose	s.c. fixed dose	s.c. fixed dose

Where possible, information in this table relates to phase 3 trial populations with blood eosinophils ≥300 cells·μL⁻¹ and using current licensed doses. Quality of life relates to AQLQ only. ^#: see Hanania et al. [25]. ^¶: the data presented relate to the subgroup with blood eosinophils ≥300 cells·μL⁻¹; this population had ≥3 exacerbations in the previous 12 months, which is higher than the other phase 3 studies. ⁺: exacerbation rate is difficult to compare across biologics due to differing study populations (e.g. moderate-to-severe asthma), different inclusion criteria (e.g. eosinophil count threshold) and size of placebo responses. ^§: see Normansell et al. [11]. ^ƒ: FEV₁ improvement: +/− indicates unclear or inconsistent results; + indicates improvement of ∼100 mL to <200 mL; ++ indicates improvement of ≥200 mL. ^##: for CRwNP: + indicates significant improvement in SNOT-22 score or severity of disease; ++ indicates improvement in both. ^¶¶: improvement with dupilumab larger magnitude than with mepolizumab/omalizumab. ⁺⁺: this may result in more than one injection to achieve the correct dose.